MMP9 and neoplasm: In preclinical models of CRC, neutrophil-secreted MMP-9 was also shown to activate TGF-β−mediated T cell suppression and tumor promotion, suggesting that targeting either TGF-β receptor or MMP-2/9 inhibitors could be a potential therapeutic strategy [34].